Showing results (1-10 of 53) with videos related to
Sort By:
Pageof 6
Frontiers in Genetics|July 30, 2019
Neural Cell Responses Upon Exposure to Human Endogenous RetrovirusesJoel Gruchot, David Kremer, Patrick KüryMultiple Sclerosis (Houndmills, Basingstoke, England)|January 28, 2015
Promoting remyelination in multiple sclerosis: current drugs and future prospectsDavid Kremer, Patrick Küry, Ranjan DuttaJournal of Orthopaedic Case Reports|November 11, 2024
Cuff Arthropathy, Scapular Spine Fracture Non-union, and Instability: Open Reduction, Internal Fixation & Simultaneous Reversed Shoulder Arthroplasty - A Case ReportStefan Bauer, Arnaud Walch, David KremerJournal of Neurology|January 6, 2019
Long-term follow-up of multiple sclerosis studies and outcomes from early treatment of clinically isolated syndrome in the BENEFIT 11 studyHans-Peter Hartung, Jonas Graf, David KremerMultiple Sclerosis (Houndmills, Basingstoke, England)|April 10, 2018
ECTRIMS/ACTRIMS 2017: Closing in on neurorepair in progressive multiple sclerosisDavid Kremer, Patrick Küry, Hans-Peter HartungCurrent Opinion in Neurology|June 8, 2022
Endogenous clues promoting remyelination in multiple sclerosisCatherine Lubetzki, Bernard Zalc, David Kremer, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|October 2, 2018
Current advancements in promoting remyelination in multiple sclerosisDavid Kremer, Rainer Akkermann, Patrick Küry, et al.Trends in Neurosciences|March 12, 2016
Pushing Forward: Remyelination as the New Frontier in CNS DiseasesDavid Kremer, Peter Göttle, Hans-Peter Hartung, et al.Annals of Neurology|April 27, 2011
The complex world of oligodendroglial differentiation inhibitorsDavid Kremer, Orhan Aktas, Hans-Peter Hartung, et al.Cell Cycle (Georgetown, Tex.)|September 5, 2008
p57 kip2's role beyond Schwann cell cycle controlAndré Heinen, David Kremer, Hans-Peter Hartung, et al.Pageof 6